Funding Announcement: Upstream Bio Secures $200 Million in Series B Round to Lead the Fight Against Inflammation

Upstream Bio is thrilled to announce that we have successfully raised $200 million in our latest funding round, a significant leap forward in our mission to target the source of inflammation and develop innovative therapies for patients worldwide. At the forefront of our efforts is our lead program, a clinical-stage monoclonal antibody designed to inhibit the TSLP receptor. TSLP, or thymic stromal lymphopoietin, is a crucial player positioned upstream in diverse signaling pathways that influence various immune cells involved in both common and rare inflammatory and allergic diseases. With this substantial investment, we are strategically equipped to accelerate our research and development initiatives, bringing us closer to our vision of alleviating the burden of these conditions on patients and their families. This funding will enable us to enhance our clinical trials, recruit top-tier talent, and expand our therapeutic pipeline, as we harness our team’s extensive industry experience and diverse backgrounds to foster innovation. At Upstream Bio, we believe that breakthroughs in understanding the immune system’s complexity can lead to transformative treatments for many individuals suffering from inflammatory diseases. With this capital, we are committed to paving the way for novel solutions that not only address the symptoms but also treat the underlying causes of these ailments, ultimately improving the quality of life for countless patients. Thank you to our investors who share our vision and trust in our mission; together, we are ready to lead a new chapter in therapeutic development.